Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

THE TRUTH ABOUT: Novavax has limited pipeline upside says bofa analyst what s next - The Untold Story

Although Novavax, Inc’s (NASDAQ:NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities.

The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.